Unlike earlier G12C-specific "RAS-off" drugs that lock KRAS in an inactive state, new "RAS-on" inhibitors form a tri-complex with an active form of RAS and an endogenous protein. This novel mechanism enables targeting of a much broader spectrum of RAS mutations, representing a significant breakthrough for treating pancreatic cancer.

A new class of KRAS inhibitors targets the active 'on-state' of the protein, a departure from earlier drugs that targeted the inactive 'off-state'. These 'tri-complex inhibitors' use a chaperone protein to bind to the active GTP-bound KRAS, preventing downstream signaling and creating a new therapeutic avenue.

A new class of drugs, "RAS on" inhibitors (e.g., daxorarasib), targets the active, GTP-bound state of KRAS. This mechanism is distinct from first-generation "RAS off" inhibitors (e.g., sotorasib) and is designed to treat patients who develop resistance, offering a subsequent line of targeted therapy.

Contrary to the idea that a pan-RAS inhibitor is superior, Varistem suggests a more targeted approach. Patients should first receive an inhibitor specific to their mutation (e.g., G12D). If resistance develops via a new RAS mutation, then a broader pan-RAS inhibitor should be used, creating a more rational, sequential treatment paradigm.

The next therapeutic frontier for RAS-mutated cancers involves combining multi-selective RAS inhibitors (e.g., daraxonrasib) with mutation-specific inhibitors (e.g., zoldon-rasib). This dual-pronged strategy aims to achieve deeper and more durable pathway inhibition by attacking the target through different mechanisms simultaneously.

The new drug avutometinib uses a "RAF-MEK clamp" mechanism, blocking two nodes in the RAS pathway simultaneously (RAF and MEK). This dual-inhibition strategy is more effective than single-node targeting because it preempts the cancer cell's adaptive resistance mechanisms, where the pathway reactivates itself in response to upstream blocking.

There is emerging evidence for sequencing KRAS inhibitors based on their mechanism. The "on-state" inhibitor Eliron-RASIB has shown a 50% response rate in patients previously treated with "off-state" inhibitors like adagrasib, suggesting that the resistance mechanism determines the effectiveness of subsequent therapy.

While pan-RAS inhibitors like daraxoracib show broad efficacy irrespective of mutation, allele-specific agents may have fewer side effects and more predictable resistance patterns. This creates a clinical trade-off between immediate applicability and a more tailored, potentially better-tolerated long-term strategy.

The CEO, motivated by personal loss, states that the current one-year survival gain from new RAS inhibitors is not enough. The true path to long-term survival lies in developing intelligent combinations. Varistem is even planning to combine its specific G12D inhibitor with a competitor's pan-RAS inhibitor to tackle resistance and improve durability for patients.